Legend Biotech's Race to Make Cell Therapy Mainstream
Update: 2025-09-09
Description
“Once a scientist, forever a scientist,” says Legend Biotech CEO Ying Huang as he joins Bloomberg Intelligence analyst Sam Fazeli to share his unconventional journey from the lab bench to Wall Street and back to biotech leadership. Dr. Huang explains how a dream led him from equity research to developing one of the most important CAR-T therapies for multiple myeloma. They explore the science behind BCMA targeting, lessons from the pivotal Johnson & Johnson partnership as well as the company’s ambitions in allogeneic and in-vivo therapies.
See omnystudio.com/listener for privacy information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
